The startup develops a bispecific antibody platform that utilizes immunotherapy to enhance the immune system's ability to target and eliminate cancer cells. This technology aims to provide effective cancer treatments with minimized side effects, improving patient outcomes in oncology.
Funding
$36.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to completely eradicate tumors and can cause significant side effects due to their impact on healthy cells. Immunotherapies hold promise, but their efficacy can be limited by the immune system's inability to effectively target and eliminate cancer cells without causing excessive toxicity.
Solution
NovalGen is a clinical-stage company developing multi-specific antibody therapies designed to enhance patient outcomes across autoimmune, oncological, and other immunological disorders. The company's proprietary autoregulation platform technology integrates self-regulating capabilities into immunotherapies, improving clinical outcomes with safer treatment strategies. NovalGen's antibodies target the Frizzled domain of ROR1, a binding site for many ROR1 ligands, enabling the antagonism of signaling. This approach allows for more efficient immune synapse formation, enhancing the cytotoxic efficacy of T cell engagers and CAR-T cells.
Target Audience
The primary target audience includes patients with autoimmune diseases, cancer, and hematological malignancies, as well as the healthcare providers who treat them.
Features
- Proprietary autoregulation platform technology that integrates biosensors into therapeutic molecules to limit life-threatening toxicities
- ROR1-targeting antibodies that bind to the Frizzled domain, antagonizing signaling and enabling more efficient immune synapse formation
- Bispecific T cell engagers (TCEs) that redirect the body’s own immune system to eradicate tumor cells
- NVG-111: A first-in-class bispecific TCE antibody targeting ROR1-expressing tumors, designed to kill cancer cells without depleting normal B cells
- NVG-222: An extended-half-life version of NVG-111 with proprietary auto-regulation technology for enhanced safety and a wider therapeutic window
- NVG-333: A next-generation ROR1-targeting armored CAR-T cell with inducible secretion of a dual payload in response to tumor cell engagement
- NVG-444: A next-generation bispecific antibody with proprietary auto-regulation technology aimed at different targets